Progranulin (GRN) (PGRN)

Progranulin (PGRN) is a 68 kDa pleiotropic secreted glycoprotein encoded by the GRN gene that plays a vital role in lysosomal homeostasis, cell survival, and the modulation of inflammation (UniProt: P28799). The term cellular machinery for GRN expression refers to the integrated biological processes—including transcription, translation, and receptor-mediated trafficking (e.g., via Sortilin-1)—that determine the steady-state levels of functional PGRN in the brain and periphery (PubMed: 28289652). Mutations in the GRN gene, typically resulting in haploinsufficiency, are a major genetic cause of Frontotemporal Dementia (FTD-GRN), leading to lysosomal dysfunction and the pathological accumulation of TDP-43 aggregates (PubMed: 30651241). Therapeutic interventions targeting this machinery aim to restore PGRN levels to a physiological range. Current clinical strategies include monoclonal antibodies like Latozinemab that block Sortilin-mediated degradation, gene therapies (e.g., PR001) to deliver functional GRN copies, and antisense oligonucleotides or small molecules designed to enhance endogenous expression (ClinicalTrials.gov: NCT04374136). Monitoring PGRN levels in the cerebrospinal fluid and plasma serves as a critical biomarker for clinical efficacy in these programs.

Other names

Granulin precursorProepithelinPC cell-derived growth factorPCDGFAcrograninGranulin

Inhibition of Sortilin-mediated degradation to increase extracellular PGRN levels; AAV-mediated gene replacement to restore GRN expression; Transcriptional modulation to enhance endogenous production.